NFA
CASC

Nationwide Fund Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Nationwide Fund Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-22,092
Closed -$90K – 2988
2017
Q3 		$90K Buy
22,092
+2,956
+15% +$11.3K ﹤0.01% 2942
2017
Q2 		$71K Buy
+19,136
New +$75.9K ﹤0.01% 3009
2016
Q2 		– Sell
-10,169
Closed -$77K – 3348
2016
Q1 		$77K Hold
10,169
– – ﹤0.01% 2896
2015
Q4 		$135K Sell
10,169
-422
-4% -$7.27K ﹤0.01% 2733
2015
Q3 		$174K Sell
10,591
-505
-5% -$10.4K ﹤0.01% 2641
2015
Q2 		$249K Buy
11,096
+454
+4% +$7.18K ﹤0.01% 2588
2015
Q1 		$104K Buy
10,642
+517
+5% +$5.07K ﹤0.01% 2950
2014
Q4 		$115K Buy
10,125
+865
+9% +$9.39K ﹤0.01% 2873
2014
Q3 		$107K Buy
9,260
+459
+5% +$7.01K ﹤0.01% 2968
2014
Q2 		$171K Buy
+8,801
New +$155K ﹤0.01% 2826
2013
Q3 		– Sell
-4,233
Closed -$40K – 3302
2013
Q2 		$40K Buy
+4,233
New +$54.4K ﹤0.01% 2998

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nationwide Fund Advisors's CASC Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2017, closing a stake of 22,092 shares — an estimated $90K sold.

Nationwide Fund Advisors first reported a position in CASC in Q2 2013 and held it in 11 quarters. The position peaked at $249K in Q2 2015. 91 funds tracked by Wall St. Rank hold CASC as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 22,092 Cascadian Therapeutics, Inc. shares in Q4 2017, an estimated $90K.
  • Nationwide Fund Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
  • Nationwide Fund Advisors's Cascadian Therapeutics, Inc. position peaked at $249K in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.